Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

272 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recovery of Third, Fourth, and Sixth Cranial Nerve Palsies in Pituitary Adenoma and Meningioma Patients.
Lu LJ, Pelsma ICM, de Vries F, van Hulst-Ginjaar SPA, van Furth WR, Verstegen MJT, Fisher FL, Zamanipoor Najafadabadi AH, Biermasz NR, van der Meeren SW, Notting IC. Lu LJ, et al. Among authors: biermasz nr. J Neuroophthalmol. 2024 Sep 1;44(3):406-413. doi: 10.1097/WNO.0000000000001990. Epub 2023 Sep 4. J Neuroophthalmol. 2024. PMID: 37669254 Free PMC article.
Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).
van Haalen FM, Kaya M, Pelsma ICM, Dekkers OM, Biermasz NR, Cannegieter SC, Huisman MV, van Vlijmen BJM, Feelders RA, Klok FA, Pereira AM; Endo-ERN Cushing and Thrombosis study group. van Haalen FM, et al. Among authors: biermasz nr. Orphanet J Rare Dis. 2022 May 3;17(1):178. doi: 10.1186/s13023-022-02320-x. Orphanet J Rare Dis. 2022. PMID: 35505430 Free PMC article.
Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment.
Boertien TM, Drent ML, Booij J, Majoie CBLM, Stokkel MPM, Hoogmoed J, Pereira AM, Biermasz NR, Simsek S, Veldman RG, Weterings AJ, Vink JM, Tanck MWT, Fliers E, Bisschop PH. Boertien TM, et al. Among authors: biermasz nr. Lancet Reg Health Eur. 2024 May 13;42:100923. doi: 10.1016/j.lanepe.2024.100923. eCollection 2024 Jul. Lancet Reg Health Eur. 2024. PMID: 39070749 Free PMC article.
Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).
Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, Freda P, Gadelha M, Haberbosch L, Kaiser UB, Lamberts S, Laws E, Nachtigall LB, Popovic V, Reincke M, van der Lely AJ, Wass JAH, Melmed S, Casanueva FF. Giustina A, et al. Among authors: biermasz nr. Pituitary. 2024 Aug;27(4):381-388. doi: 10.1007/s11102-024-01397-w. Epub 2024 Jun 4. Pituitary. 2024. PMID: 38833044 Free PMC article.
18F-fluoro-ethyl-tyrosine PET co-registered with MRI in patients with persisting acromegaly.
Bakker LEH, Verstegen MJT, Manole DC, Lu H, Decramer TJM, Pelsma ICM, Kruit MC, Verbist BM, van de Ven A, Gurnell M, Ghariq I, van Furth WR, Biermasz NR, Pereira Arias-Bouda LM. Bakker LEH, et al. Among authors: biermasz nr. Clin Endocrinol (Oxf). 2024 Aug;101(2):142-152. doi: 10.1111/cen.15079. Epub 2024 May 31. Clin Endocrinol (Oxf). 2024. PMID: 38818709
272 results